AVITA Medical’s Cohealyx Cuts Time to Skin Grafting by 20 Days in Trial Data
AVITA Medical’s Cohealyx interim data shows 20-day reduction in time to skin grafting
AVITA Medical has reported positive interim results from its Cohealyx-I study, demonstrating a mean time to skin grafting of 13.6 days compared to a real-world benchmark of 33.2 days — representing an approximate 20-day reduction. The results showed statistical superiority (p<0.001) versus a literature-derived benchmark based on approximately 900 patients using leading dermal matrices.
The interim analysis of 40 patients revealed a median time to grafting of 11 days, with grafting achieved as early as 5 days in some cases. Investigators reported 90% satisfaction at the time of grafting, including among predominantly first-time users, supporting the potential for broader clinical adoption.
The benchmark was derived from a meta-analysis of published data on leading dermal matrices, with the lower bound of the 95% confidence interval established at 28 days.
When big ASX news breaks, our subscribers know first
What is Cohealyx and why does time to grafting matter?
Cohealyx is a collagen-based dermal matrix designed to support vascularisation and optimise the wound bed for closure in patients with full-thickness wounds. The product is intended for use in staged surgical procedures, where Cohealyx is applied to the wound bed following surgical excision, and autografting is performed once adequate vascularisation has been achieved.
Reducing time to grafting is clinically significant because it directly impacts patient outcomes through shorter hospital stays, reduced infection risk, and faster wound closure. For hospitals, accelerated healing times translate to improved bed turnover and reduced treatment costs, creating a compelling value proposition for procurement decisions.
Cohealyx integrates with AVITA’s broader wound care portfolio, which includes RECELL (Spray-On Skin) and PermeaDerm, a biosynthetic wound matrix. This platform approach positions the company to address multiple stages of the wound healing pathway rather than relying on a single therapeutic solution.
Interim study results in detail
The 40-patient interim analysis demonstrated accelerated wound bed preparation across diverse wound types. Grafting was achieved as early as 5 days in the fastest cases, with 25% of patients grafted within 7 days and 72% grafted within 14 days.
Investigator satisfaction reached 90% at the time of grafting, a notable outcome given that the majority of participating clinicians were first-time Cohealyx users. This suggests a low learning curve and supports the product’s scalability beyond specialist burn centres.
| Metric | Result |
|---|---|
| Patients analysed | 40 |
| Median time to grafting | 11 days |
| Earliest grafting achieved | 5 days |
| Grafted within 7 days | 25% |
| Grafted within 14 days | 72% |
| Investigator satisfaction | 90% |
The high satisfaction rate among first-time users indicates consistent product performance and suggests broader clinical adoption may be achievable without extensive training requirements.
Key opinion leader commentary
Derek Bell, MD, Professor of Plastic Surgery and Kessler Burn Director, University of Rochester Medical Center
“These interim results show that Cohealyx supports vascularization and enables earlier grafting, which is central to improving patient outcomes. Importantly, these results were achieved across a myriad of diverse and complex wounds.”
Dr Bell’s commentary underscores the clinical validation of Cohealyx across diverse wound presentations, indicating broad applicability beyond specific wound types or patient populations. The diversity of wound types treated in the study supports the product’s potential utility across burn centres, trauma units, and reconstructive surgery settings.
Commercial implications and AVITA’s wound care platform
The interim data strengthens AVITA’s competitive positioning in the dermal matrix segment, where time to grafting is a key differentiator. Cohealyx’s performance supports its potential to capture market share from established dermal matrices that demonstrate longer healing timelines.
AVITA’s strategy centres on owning multiple stages of the wound healing pathway through its integrated product platform. RECELL addresses autografting with Spray-On Skin technology, while PermeaDerm provides biosynthetic wound coverage. Cohealyx completes the portfolio by optimising wound bed preparation ahead of grafting.
This multi-product approach creates cross-selling opportunities within burn centres and trauma units, potentially increasing revenue per customer and strengthening hospital relationships through a comprehensive wound care solution.
Cary Vance, Interim Chief Executive Officer, AVITA Medical
“This data strengthens our belief that Cohealyx can set a new benchmark in wound bed preparation. The meaningful reduction in time to grafting and high investigator satisfaction highlight its potential as a differentiated solution with the ability to drive broader adoption as we work to improve each stage of the wound healing pathway.”
Management’s focus on improving each stage of the healing pathway signals a long-term strategy to build an ecosystem of complementary products rather than pursuing individual product launches in isolation.
The next major ASX story will hit our subscribers first
Next steps and upcoming catalysts
The Cohealyx-I study remains ongoing, with the full dataset expected in 2026. Patients enrolled in the trial are followed for approximately six months post-grafting to assess durability of outcomes and monitor adverse events.
AVITA Medical has scheduled near-term data dissemination events that provide opportunities for broader market awareness:
- Full Cohealyx-I study results expected 2026
- KOL webinar: Wednesday, April 16, 2026, 4:30pm ET (Thursday, April 17, 6:30am AEST)
- Symposium presentation: Wednesday, April 15, 2026, at American Burn Association Annual Meeting
The symposium presentation will be delivered by Dr Derek Bell and Dr Jonathan E. Schoen, Medical Director of the UMCNO Verified Burn Centre and Associate Professor of Clinical Surgery at LSUHSC School of Medicine at New Orleans.
The April 16 webinar will feature Dr Bell and Dr Lourdes Castañón of the University of Arizona, reviewing the interim data and case studies. The webinar is accessible to investors via direct webcast, with a replay available on the AVITA Medical investor relations website following the event.
These catalysts provide multiple touchpoints for market re-rating as full data emerges and clinical validation strengthens through peer presentation and key opinion leader engagement.
Don’t Miss the Next Biotech Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving biotech and healthcare announcements break.